Progress in understanding tumor-specific immune responses, genetic engineering and ex vivo manufacturing, have led to improvements in the safety and feasibility of adoptive transfer of genetically modified T cells. However, rational design, application and evaluation of T-cell therapy requires monitoring methods that can detect, locate and serially quantify these cell-mediated immune responses. Currently, such monitoring methods are chiefly limited to invasive techniques to investigate recovered cell populations for in vitro measurements including histology, flow cytometry, Q-PCR or the detection of cytokines. These assays provide episodic glimpses of the bio distribution of T cells and are limited by the number and sites of sampling. In contrast, imaging provides a methodology for quantitative, non-invasive, longitudinal and spatial in vivo information about the dynamic processes of infused T cells.
In earlier studies, in vivo imaging of lymphocyte migration used cells passively labeled with radiotracers ex vivo. An alternative imaging approach involves stable transduction/ transfection of cells with a reporter gene (such as herpes simplex virus-1 thymidine kinase; HSV-TK) that can be visualized by active accumulation of a radiolabeled reporter probe. It has been demonstrated that cells genetically modified to express HSV-TK could be imaged by scintigraphy or positron emission tomography (PET) in rodents after infusions of I-labeled
Bioluminescence imaging (BLI) of luciferase reporter gene expression has also been used to monitor lymphocyte trafficking in a mouse model. 2, 3 Recently Dobrenkov et al. 4 have shown the feasibility of PET and BLI in a prostate cancer model using peripheral blood chimeric antigen receptor (CAR) þ cells and Jensen and co-workers have evaluated the biodistribution of CAR þ T cells by magnetic resonance imaging. 5 Previously, we have demonstrated that human T cells derived from peripheral blood and umbilical cord blood (UCB) mononuclear cells can be rendered specific for CD19 by the introduction of a CAR. 3, 6 To track the persistence of infused genetically modified T cells, a multi-function reporter gene (designated ffLucHyTK) was developed which fuses firefly luciferase (ffLuc), hygromycin phosphotransferase (Hy) and HSV-TK ( Figure 1) . 2, 3 The four-function reporter transgene can F-fluoro-arabinose was then converted to its 1-bromo-derivative, which was condensed with protected 5-ethyluracil. Hydrolysis of the protecting groups in the sugar moiety with NaOMe produced the desired radiolabeled nucleoside, which was purified by HPLC. Solvent was evaporated, and then the product was re-constituted in saline and filtered through a 0.22 m Millipore filter. The radiochemical yield was 20% (decay corrected, d.c.) from the end of bombardment. Radiochemical purity was 499% and specific activity was 474 GBq/mmol. (d) In vitro radiotracer uptake study, genetically modified or unmanipulated T cells ( 10 7 ) were centrifuged (1000 g, 5 min) and the pellet was resuspended in 6 ml of RPMI media containing 10% fetal bovine serum and the radiotracers [
14 C]-thymidine (0.01 mCi/ml) (Moravek, Brea, CA, USA) and [ 3 H]-FEAU (0.1 mCi/ml) (Moravek). The cell suspension was subsequently divided into three 10 mm 2 dishes (2 ml per dish) and incubated for 120 min. Each suspension was then transferred into a 15 ml tube, and centrifuged at 1000 g for 2 min. A 100 ml aliquot of supernatant was transferred to a pre-weighed scintillation tube, and the rest was removed by aspiration before snap-freezing the cell pellet on dry ice. The frozen pellets were transferred to pre-weighed scintillation vials, weighed and thoroughly resuspended in 0.5 ml of Soluene-350 (Perkin-Elmer, Boston, MA, USA) before adding 4 ml of Insta-Fluor Plus scintillation fluid (Perkin-Elmer). Radioactive b emissions of the media and the cell pellets were measured within precalibrated energy ranges using a Packard Tri-Carb 3100TR scintillation counter to quantitate [ achieve (i) in vitro selection of genetically modified T cells in cytocidal concentrations of hygromycin B, (ii) in vivo ganciclovirdependent conditional ablation 7 and in vivo imaging with (iii) BLI with (iv) PET. A DNA plasmid expressing the fusion gene was expressed in T cells to render them resistant to cytocidal concentrations of hygromycin B and thus co-express the ffLuc and TK imaging genes.
This was achieved using UCB-derived T cells that underwent electro-transfer with the plasmid ffLucHyTK-pMG (Figure 1a) . We demonstrated that the genetically modified and propagated TK þ T cells could be visualized by selective incorporation of radiolabeled 2 0 -fluoro-2 0 deoxy-1-b-D-arabionofuranosyl-5-ethyl-uracil (FEAU) in a xenogenic mouse model. Radiolabeled FEAU is a specific substrate for HSV1-TK enzyme, which accumulates in HSV1-TK-transfected cells through phosphorylation by the HSV1-TK enzyme, and that the magnitude and spatial distribution of accumulation of FEAU-derived radioactivity in the body reflects the location and density of TK To visualize genetically modified UCB-derived T cells by BLI and mPET, nude mice were injected subcutaneously (right hind leg) or intravenously through tail vein and imaged using an ultrasensitive CCD camera followed by a mPET scan. Bioluminescent images after intraperitoneal injection of D-Luciferin revealed that genetically modified T cells express high bioluminescence (2.22 Â 10 5 p/sec/cm 2 /sr) in comparison to the control (left uninjected leg) (0.29 Â 10 5 p/sec/cm 2 /sr). These mice were then imaged by mPET using intravenous infusion of [ 18 F]FEAU and static images were obtained. The signal from the images was used to determine % injected dose (ID)/g of FEAU which is a measure of the amount of tracer accumulated in a given tissue site normalized to the injected amount and to the mass of tissue examined. The %ID/g value for genetically modified T cells (7.9%) was higher than the control (muscle, 1.61%) (Figure 2a) . After intravenous infusion of genetically modified UCB-derived T cells, the cells could be visualized in the lung both by BLI and mPET. Ratio of bioluminescent signals from lungs and control tissue (abdomen) was 36. PET images reveal the accumulation of radiotracer in the lungs along with the urinary bladder (Figure 2b) .
These data indicate that the genetically modified UCB-derived T cells expressing the ffLucHyTK fusion transgene can uptake PETtracer in vitro and can be visualized spatiotemporally in vivo by both BLI and mPET. As the ffLucHyTK is similar to the HyTK transgene used in clinical trials 9 these data can be used to provide the proof-ofprinciple for instituting PET imaging after infusion of donor-derived T cells following UCB transplantation. This is the first report demonstrating that HyTK fusion gene can be used not only for selection and suicide, 3 but also for PET using T cells from UCB. This has translational importance as the TK and HyTK transgenes are currently used in clinical trials, 7, 9 where coexpression of the TK suicide gene may be necessary to ensure safety of initial protocols infusing genetically modified T cells. As 
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investigators proceed with infusing genetically modified T cells, including from umbilical cord blood, the incorporation of PET imaging is expected to be a useful biologic end point.
Survivin, an inhibitor of apoptosis protein (IAP) family member, is expressed during fetal development and was reported to be undetectable in terminally differentiated adult tissues. 1 More recent studies have shown that survivin expression is also high in immature bone marrow neutrophil precursors and can be detected in terminally differentiated neutrophils from patients with chronic inflammation.
2 Survivin is also prominently expressed in most common cancers and is associated with chemoresistance and poor prognosis, making survivin-targeted therapies an attractive cancer treatment strategy. 1, 3 Severe congenital neutropenia (SCN) is a heterogenous group of primary immunodeficiencies in which a lack of neutrophils causes inadequate immune responses to bacterial infections. Patients suffering from autosomal recessive SCN (also known as Kostmann disease) display a characteristic maturation arrest at the promyelocyte/myelocyte stage of myelopoiesis, and our previous studies have demonstrated that this maturation arrest is associated with mitochondria-dependent apoptosis of myeloid progenitor cells. 4 Moreover, recent studies have identified homozygous mutations in the antiapoptotic gene encoding HAX-1 in patients with Kostmann disease, including patients belonging to the original kindred described by Rolf Kostmann in northern Sweden.
5
Lymphoid enhancer-binding factor-1 is a transcription factor that has been implicated in the proliferation, survival and differentiation of neutrophil progenitors. A previous study has shown that the expression of lymphoid enhancer-binding factor-1 is diminished or even absent in the bone marrow of SCN patients with a classical maturation arrest of the myelopoiesis. 6 Of considerable interest, expression of the lymphoid enhancer-binding factor-1 target gene, survivin, was also shown to be defective in myeloid precursors from SCN patients. On the basis of these findings, defective survivin expression was proposed to be one of the key events underlying the enhanced apoptosis of myeloid progenitors in SCN patients. 6 However, survivin expression was not assessed at the protein level in these studies. To further our understanding of the potential role of survivin in SCN, we performed a semiquantitative assessment of survivin protein expression in the bone marrow of 6 SCN patients, including three patients belonging to the original Kostmann family. Patient characteristics are reported in Table 1 . Homozygous HAX1 mutations were
